updat model reflect revis guidanc guidanc look conserv
view rais less beat impli unusu
progress vs histor along faster synergi realiz improv
sell season guid look achiev rais pt
reiter outperform
believ guidanc may prove conserv particularli management rais
adj ep guidanc top-end bottom-end despit
beat quarter addit guidanc guidanc impli unusu back-
half quarterli progress adj ep q/q even though typic
strongest quarter year adj ep basi expect moder q/q
increas adj ep given hcb adj oper profit decreas
sequenti normal season increas medic cost member work
deduct well increas oper expens due enrol cost
sequenti pharmaci servic adj oper profit growth flatten rel due
pronounc impact rolloff howev sequenti declin
adj ep impli modest sequenti growth retail/ltc adj oper profit
recent year better expect perform retail/ltc far
year progress impli guidanc seem less like view
see management guidanc greater adj ep achiev
see upsid current consensu follow develop
given initi adj ep guidanc proven conserv see upsid
guidanc faster expect synergi realiz improv
sell season benefit faster expect synergi realiz formulari
optim transit function pharmaci servic management note quarter
benefit well net loss sell season improv
provid analyst day improv sell season
benefit pharmaci servic retail/ltc well would expect
see upsid oper profit guidanc mid-singl digit pharmaci
servic low-singl digit retail/ltc provid analyst day note
revis adj ep estim assum pharmaci servic oper profit
vs previous retail/ltc vs previous
rais adj ep estim
respect also rais price target base revis
dcf analysi impli share trade adj ep estim
pleas see page report import disclosur
posit long-term strategi coordin care combin
legaci asset aet broader healthcar system continu transit toward
value-bas care believ potenti bring differenti model
market gain share and/or improv profit demonstr
valu proposit market management believ improv outcom lower cost
manag chronic condit use healthhub leverag telemedicin non-
physician provid furthermor view share under-valued current level
valuat suggest market assum overli pessimist outlook
detail regard mitig headwind
progress integr aet
merger achiev synergi target
increment inform l-t
strategi potenti revenu
top-lin growth primarili due
acquisit aet
adj oper margin modestli
y/i due higher margin profil
assum share repo
strong revenue growth due retail comp
slower expect rolloff
faster expect rollon
greater expect contribut
gener stronger expect
faster expect synergi ramp
lower expect invest
weak revenue growth due retail comp
faster expect rolloff
slower expect rollon
lower expect contribut
gener wors expect brand
slower expect synergi ramp
higher expect invest
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg elimination- net benefit gross gross bp chang y/y- oper oper oper bp chang y/y- adj oper adj oper bp chang y/y- interest expens pre-tax pre-tax bp chang y/y- adj incom tax provis effect tax rate effect tax adj net adj net incom bp chang y/y- earn alloc particip net incom attribut non-controlling adj net incom attribut net weight averag dilut share adj pharmaci servic gross gross adj oper adj oper total adj gross profit/adj retail/ltc gross gross oper oper retail store increas decreas total pharmaci front store benefit segmentrevenue- oper profit- oper cowen
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work terminal- valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg net benefit gross gross chang y/y- oper oper chang y/y- adj oper adj oper chang y/y- interest expens pre-tax pre-tax chang y/y- adj incom tax provis effect tax rate tax net adj net incom chang y/y- earn alloc particip net incom attribut non-controlling adj net incom attribut intang acquisition-rel financ goodwil impair long-liv loss divestitur net interest expens financ associ adj incom tax earn alloc particip net incom attribut non-controlling gaap net weight averag dilut share adj gaap chang y/i net oper net net incom attribut end decemb cowen
million except per-shar data
cowen compani
interseg net good interseg net cost good benefit interseg elimination- net benefit gross gross chang oper oper chang adj oper adj oper chang interest expens pre-tax pre-tax chang adj incom tax provis effect tax rate tax net adj net incom chang earn alloc particip net incom attribut non-controlling interest- adj net incom attribut intang acquisition-rel financ goodwil impairment- impair long-liv assets- store ration charge- loss divestitur net interest expens financ associ tax earn alloc particip net incom attribut non-controlling interest- net weight averag dilut share adj chang y/i net oper net net incom attribut cowen
million
cowen compani
cash short-term account receiv current current long-term properti equip intang asset separ account assets- total liabil account pharmaci claim discount care cost policyhold funds- accru insur short-term current portion long-term current long-term defer incom separ account liabilities- long-term insur long-term redeem non-controlling interest- stockhold equiti common treasuri share held trust- capit surplus- retain accumul comprehens total sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale day purchas account day claim day ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti decemb cowen
million
compani report cowen compani
income/ loss adjust requir reconcil net incom net cash provid oper activ depreci goodwil loss settlement defin benefit pension plans- stock-bas loss earli extinguish debt- defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv account payabl claim discount care cost payabl insur long-term net cash oper acquisit proce sale subsidiari properti acquisit issuanc common purchas treasuri stock- dividend proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival restrict cash begin cash equival restrict cash end cowen summari capit owner financ non-recur exclud non-recur itemsyear end decemb cowen
million
compani report cowen compani
activitiesnet adjust requir reconcil net incom net cash provid oper activ depreci goodwil impairments- loss settlement defin benefit pension plans- stock-bas loss earli extinguish defer incom tax non-cash chang oper asset liabil net effect acquisit account receiv account payabl pharmaci claim discount care cost payabl insur long-term net cash provid oper invest activitiesproce sale matur purchas purchas properti proce sale-lease-back acquisit net cash proce sale subsidiari assets- net cash use invest financ activitiesincreas decreas short-term proce issuanc long-term repay long-term purchas non-controlling interest payment conting deriv settlements- dividend proce exercis stock payment tax relat net share settlement equiti repurchas common net cash provid use financ effect exchang rate net decreas cash cash cash equival restrict cash begin cash equival restrict cash end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
slower-than-expect onboard contract
